Table 5 Characteristics of the selected studies
Study | Country | Study type | Groups | Agea | Gender (M/F) | Follow-up (months)a | Diagnosis of AP | Diagnosis of IPMN | NOS score |
|---|---|---|---|---|---|---|---|---|---|
Tanaka 2020 | Japan | Case control study | AP: 20 | 69 (43 ~ 81) | 12/8 | 48 (12 ~ 144) | Japanese guidelines; strict control of confounding factors | Histology; Consensus Guideline | 8 |
non-AP: 162 | 69 (43 ~ 86) | 96/66 | |||||||
Morales-Oyarvide 2015 | USA | Case control study | AP: 69 | 61 ± 12.4 | 35/34 | 58 (2 ~ 108) | Medical records; basic control of confounding factors | Histology; Consensus Guideline | 6 |
non-AP: 256 | 70 ± 9.5 | 124/132 | |||||||
Hata 2013 | Japan | Case control study | AP: 12 | 65 (35 ~ 73) | 7/5 | Not available | The Atlanta Standard; strict control of confounding factors | Histology; Consensus Guideline | 7 |
non-AP: 76 | 65.5(41 ~ 82) | 47/29 | |||||||
Tsutsumi 2010 | Japan | Case control study | AP: 19 | 70.0 ± 8.2 | 11/8 | Not available | JPN standard; basic control of confounding factors | Histology; Consensus Guideline | 7 |
non-AP: 131 | 66.0 ± 8.6 | 82/49 | |||||||
Pelletier 2010 | France | Case control study | AP: 64 | 65 (38 ~ 75) | 49/15 | 24 (1 ~ 168) | French Consensus; Strict Control of Confounding Factors | Histology | 6 |
non-AP: 121 | 57 (28 ~ 75) | 44/77 |